Chongqing Pharscin Pharmaceutical Co.Ltd(002907) R & D investment increased by 80% in 2021

Chongqing Pharscin Pharmaceutical Co.Ltd(002907) on February 16, the annual performance express of 2021 was released. Last year, the company achieved an operating revenue of 846 million yuan, a year-on-year decrease of 4.11%; The net profit attributable to the parent company was 93.1614 million yuan, a year-on-year decrease of 21.84%, and the earnings per share was 0.2322 yuan.

As for the decrease in operating revenue, the company explained that it was mainly due to the sharp decline in the sales revenue of the cooperative variety “orlistat capsule” with Zhien biology. If this factor is excluded, the operating revenue of the company increased by 8.11% year-on-year during the reporting period. At the end of the reporting period, the company further reached an agreement with Zhien biology to commercialize orlistat capsule under its own brand “Quchang”. The company said that with the gradual implementation of the commercialization plan of “Quchang”, the sales revenue of this variety will be boosted in the future.

In addition, the company’s five exclusive proprietary Chinese medicine varieties achieved a year-on-year increase of 19.86% in sales revenue last year, showing a rapid growth trend; The sales revenue of chemical drugs and the operating revenue of pharmaceutical business have decreased due to changes in industries such as centralized procurement, showing a slowdown or stagflation trend. However, with the continuous introduction of new products to the market, the company believes that it will provide strong support for the growth of revenue scale in the future.

In terms of R & D and innovation, the company’s investment in R & D and innovation continued to increase by 90.7% year-on-year, regardless of the reason for the further increase in R & D and innovation of generic drugs during the reporting period. In addition, the decrease of government subsidies, the increase of sales expenses and depreciation expenses, and the decline of average sales price and gross profit margin caused by centralized purchase of varieties also constitute various reasons for the reduction of profits.

- Advertisment -